Table 2. Percentage and relative risks for promoters affecting the transition rate from the pre-clinical screen-detectable phase (PCDP) to the clinical phase (CP).
| Variables | Percentage (%) of breast cancer in the PCDP (pre-symptomatic cases) | Relative risk of the progression from the PCDP to the CP (symptomatic cases) | References |
|---|---|---|---|
|
BMI (kg m−2) | |||
| ⩽23 | 26.20a | 1.00 | Hsieh et al, 2002 |
| >23 |
73.80a |
2.00 |
Chen et al, 2004 |
|
Age at full-term first pregnancy (years) | |||
| ⩽25 | 57.62a | 1.00 | Hsieh et al, 2002 |
| >25 |
42.38a |
1.56 |
Chen et al, 2004 |
|
ER status | |||
| Positive | 81.00 | 1.00 | Dong et al, 2008 |
| Negative |
19.00 |
1.35 |
|
|
Ki-67 proliferation | |||
| <10% | 30.1 | 1.00 | Dong et al, 2008 |
| 10–30% | 50.7 | 1.40 | |
| >30% |
19.2 |
2.11 |
|
|
HER-2/neu immunohistochemistry score | |||
| 0 or 1+ | 75.6 | 1.00 | Dong et al, 2008 |
| 2+ | 11.9 | 1.28 | |
| 3+ | 12.5 | 1.07 | |
a
These values are based on the simulated PCDP (pre-symptomatic cases) simulated from free of breast cancer to the PCDP following the distribution of women free of breast cancer in Table 1.